Kieffer Tara Lynn

Insider profile

Performance

Overall performance
2.6

Performance over holding periods
2.6
30 days 90 days 120 days
Average return 2% 8.2% 15.1%
Success rate 70% 68% 82%
Transactions
3 0% Buy
34 71% Buy
47 69% Buy
Kieffer Tara Lynn's trades of Enanta Pharmaceuticals Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2025-12-05 2025-12-05 S Sale
67,949 +12.6%
252.71
US$3,765,098
67,949 +12.6% 252.71 US$3,765,098
2024-12-10 2024-12-06 S Sale
47,890 -32.2%
112.83
US$2,106,721
47,890 -32.2% 112.83 US$2,106,721
2024-06-17 2024-06-17 PrS Proposed sale
50,853
99.26
US$4,945,224
50,853 99.26 US$4,945,224
2024-06-17 2024-06-17 PlS Planned sale
7,266 -18.3%
12.33
US$89,590
7,266 -18.3% 12.33 US$89,590
2023-12-06 2023-12-05 S Sale
2,125 -5.4%
9.63
US$20,464
2,125 -5.4% 9.63 US$20,464